A new class of cholesterol-lowering medicines may struggle to meet sales projections, as latest treatment guidelines suggest doctors should prescribe only drugs proven to help the heart. Paul Ridker, the Eugene Braunwald Professor of Medicine at Brigham and Women’s Hospital, is a lead investigator of one of the trials.
